Tavapadon effectively treats Parkinson's motor symptoms globally

A new once-daily pill, tavapadon, shows promise in treating Parkinson's disease, demonstrating safety and effectiveness in two global clinical trials for both early and advanced stages. This could offer a new treatment option. The trials, TEMPO 2 and 3, evaluated tavapadon's impact on motor symptoms. TEMPO 2 focused on newly diagnosed patients, while TEMPO 3 assessed its use as an add-on therapy for those with advanced disease experiencing motor fluctuations. Tavapadon, a D1/D5 dopamine partial agonist, may offer advantages over existing treatments, including once-daily dosing and potentially fewer side effects. Further research is ongoing to assess long-term efficacy.